Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2025 07:00 ET | Source: AltruBio Inc.

AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268’s Efficacy in T Cell-Mediated Inflammatory Models

ALTB-268 demonstrated therapeutic potential in murine models of colitis and GvHD, supporting its role as an immune checkpoint enhancer in T cell-mediated inflammatory diseases Findings reinforce...
December 03, 2024 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Formation of Scientific Advisory Board

SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company developing novel immune checkpoint enhancers to address the unmet need...
November 12, 2024 08:00 ET | Source: AltruBio Inc.

AltruBio to Participate in the Upcoming Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune checkpoint enhancers to address the unmet need...
October 28, 2024 08:00 ET | Source: AltruBio Inc.

AltruBio Presents New In Vivo data for ALTB-268 at the 9th FIMSA 2024 Congress

ALTB-268 demonstrated its anti-inflammatory effect in an acute colitis hPSGL-1 mouse model. The data confirmed that ALTB-268 acts as an immune checkpoint enhancer, downregulating T cell...
May 21, 2024 08:00 ET | Source: AltruBio Inc.

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program

Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital and existing investors aMoon Fund and Blackstone Multi-Asset...
May 01, 2024 08:00 ET | Source: AltruBio Inc.

AltruBio to Participate in Upcoming May 2024 Medical Conferences

SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
December 07, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis

SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...
September 26, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis

SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment...
August 01, 2023 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

ALTB-268 was well tolerated with no serious adverse events across all subject cohorts ALTB-268 demonstrated substantially greater biological activity than first ICE molecule, ALTB-168, enabling...
June 15, 2023 08:03 ET | Source: AltruBio Inc.

AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

SAN FRANCISCO, June 15, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of...